Ultragenyx Pharmaceutical (RARE) Other Non-Current Assets (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Other Non-Current Assets data on file, last reported at $61.0 million in Q1 2026.

• Quarterly Other Non-Current Assets fell 2.2% year-over-year to $61.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.0 million (down 2.2% YoY) and the FY2025 annual result came in at $60.0 million, down 4.76% from the prior year.
• Other Non-Current Assets grew to $61.0 million in Q1 2026 per RARE's latest filing, from $60.0 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $63.0 million in Q4 2024 and bottomed at $18.3 million in Q3 2022.
• The 5-year median for Other Non-Current Assets is $53.9 million (2024), against an average of $45.6 million.
• The widest annual swing landed in 2024, when Other Non-Current Assets surged 169.42%; it then slipped 4.76% in 2025.
• Tracing RARE's Other Non-Current Assets over 5 years: stood at $48.3 million in 2022, then advanced by 19.34% to $57.7 million in 2023, then increased by 9.21% to $63.0 million in 2024, then fell by 4.76% to $60.0 million in 2025, then increased by 1.67% to $61.0 million in 2026.
• Per Business Quant, the three latest RARE Other Non-Current Assets figures stand at $61.0 million (Q1 2026), $60.0 million (Q4 2025), and $57.9 million (Q3 2025).

Peer Comparison